Business
Biomea Fusion Announces First Patient Dosed
BMF-219 is the first irreversible covalent menin inhibitor to enter the clinicPhase I trial is enrolling patients with relapsed/refractory acute leukemias,
About this update from Biomea Fusion, Inc.
[{"type":"text","content":"BMF-219 is the first irreversible covalent menin inhibitor to enter the clinicPhase I trial is enrolling patients with relapsed/refractory acute leukemias, including those with MLL1/KMT2A gene rearrangements or NPM1 mutationsPhase I trial is expected to include up to 20 clinical sites at leading US medical centers REDWOOD CITY, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in its Phase I clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with relapsed/refractory (r/r) acute leukemias, including those with MLL1/KMT2A gene rearrangements or NPM1 mutations. “We are honored and deeply humbled by this significant milestone, which marks our successful transition to a clinical stage company. Just over four years ago, we took the concept of designing a small molecule that targets menin and brought forward BMF-219 to the clinic to significantly improve the lives of patients,” said Thomas Butler, Biomea’s Chief Executive Officer and Chairman of the Board. “I’m incredibly proud of our team for their ability to execute on this aggressive timeline. This signals how we intend to operate as a drug discovery and development organization – advancing world-class science with rapid momentum and driven by an unwavering mission to improve patient outcomes and save lives. We are pursuing a novel approach to developing best-in-class molecules with our FUSION™ System across multiple indications and anticipate announcing our next pipeline candidate in the first half of 2022.” “Since 2017, we have focused on building a world-class discovery and development team at Biomea Fusion. We have internally developed our FUSION™ System, which allows us to expeditiously target validated cancer biology with breakthrough covalent chemistry. Our pipeline assets are designed to achieve higher selectivity, deeper target inactivation and thereby afford patients a greater therapeutic window. BMF-219 is just our first asset graduating now into clinical development. Our team has evolved significantly and is set up today not only to explore the full potential of BMF-219 and the inhibition of the menin pathway but also to advance several other programs into the clinic,” said Ramses Erdtmann, President of Biomea Fusion. “We are an in...